Abstract
Treatment options are limited in patients with extensive stage small cell lung cancer (ES-SCLC) after progression on first line chemo-immunotherapy (CIT). Temozolomide (TEM) is active in ES-SCLC and has been shown to have immunomodulatory impact in patients with advanced cancers, however data are unavailable in patients after CIT. We present the final analysis of a phase 2 trial of combination nivolumab and TEM in patients with ES-SCLC as 2nd or 3rd line after progression on CIT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
